Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 445 participants.

Also called NCT07539259

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 445 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07539259
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07539259. Randomized; no masking; primary purpose treatment. Start 2026-12 (anticipated); primary completion 2029-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Regression in Left Ventricular Hypertrophy and Fibrosis in Aortic Stenosis
Acronym
RELIEF-AS
Condition
Aortic Stenosis
Intervention (Drug)
Dapagliflozin (DAPA)
Intervention (Drug)
Spironolactone (drug)
Intervention (Drug)
Spironolactone + Dapagliflozin
Intervention (Drug)
Epleronone
Lead sponsor
University College, London (class: other)

Record details

Record id
cardio:ct-nct07539259
Content hash
637e3494fbca3c8a865c21dd0a6e88dec09c24195aa405e1d0be30cadb110a01